Verition Fund Management
TARS icon

Verition Fund Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Verition Fund Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$944K Buy
15,000
+10,540
+236% +$673K ﹤0.01% 1439
2026
Q1 		$313K Buy
+4,460
New +$312K ﹤0.01% 1761
2024
Q4 		– Sell
-23,199
Closed -$763K – 3516
2024
Q3 		$763K Buy
+23,199
New +$652K ﹤0.01% 2071
2023
Q4 		– Sell
-10,600
Closed -$188K – 2670
2023
Q3 		$188K Buy
+10,600
New +$188K ﹤0.01% 1988

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Verition Fund Management's TARS Position: Q2 2026 in Review

Verition Fund Management increased its Tarsus Pharmaceuticals (TARS) stake by 236% in Q2 2026, buying an estimated $673K and bringing the position to 15,000 shares worth $944K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Verition Fund Management first reported a position in TARS in Q3 2023 and has held it in 4 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Verition Fund Management held 15,000 shares of Tarsus Pharmaceuticals worth $944K as of Q2 2026.
  • Verition Fund Management bought 10,540 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $673K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1439 holding.
  • Verition Fund Management first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.